Show simple item record

dc.contributor.authorSantos Vizcaíno, Edorta ORCID
dc.contributor.authorOrive Arroyo, Gorka
dc.contributor.authorCalvo, Alfonso
dc.contributor.authorCatena, Raúl
dc.contributor.authorFernández-Robredo, Patricia
dc.contributor.authorGarcía Layana, Alfredo
dc.contributor.authorHernández Martín, Rosa María ORCID
dc.contributor.authorPedraz Muñoz, José Luis ORCID
dc.date.accessioned2024-02-08T11:26:04Z
dc.date.available2024-02-08T11:26:04Z
dc.date.issued2011-09-24
dc.identifier.citationJournal of Controlled Release 158(3) : 443-450 (2012)es_ES
dc.identifier.issn0168-3659
dc.identifier.issn1873-4995
dc.identifier.urihttp://hdl.handle.net/10810/65597
dc.description.abstractThe field of cell microencapsulation is advancing rapidly. Particle size plays a critical role in terms of biocompatibility and limits decisively its applicability. Producing reduced size microcapsules involves broadening the possibilities to employ this technology in the treatment of many disorders. Nervous system diseases (NSD) represent a clear example of that. This work describes the feasibility of reducing the size of alginate-poly-l-lysine-alginate (APA) microcapsules up to 100 μm in a highly monodisperse way using the novel Flow Focusing technique. C2C12 myoblasts genetically engineered to express the triple reporter gene thymidine kinase-green fluorescent protein-luciferase (TGL) and secrete vascular endothelial growth factor soluble receptor 2 (VEGFR2, also known as KDR) were encapsulated for further characterization. Resulting new particles were assayed in vitro to explore whether their functionality might be affected due to the physicochemical changes arising from such dramatic size reduction. Not only were negative effects at this level not noticed in terms of cell viability, cell proliferation and KDR secretion, but once again the suitability of APA microcapsules was also reinforced against other microcapsule designs. Furthermore, the fully viable and functional biosystems were successfully administered in the intravitreous space of rats, where the activity of encapsulated cells was monitoring over 3 weeks.es_ES
dc.description.sponsorshipE. Santos thanks the “Gobierno Vasco (Departamento de Educación, Universidades e Investigación)” for receiving a PhD fellowship. This study is partially financed by the “Ministerio de Ciencia e Innovación (PET-2008-330-01)”
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationinfo:eu-repo/grantAgreement/MICIN/PET-2008-330-01
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAPAes_ES
dc.subjectmicrocapsule
dc.subjectflow focusing
dc.subjectcentral nervous disease
dc.subjectreduced size
dc.subjectintravitreous
dc.titleOptimization of 100 µm alginate-poly-L-lysine-alginate capsules for intravitreous administrationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2011 Elsevier under CC BY-NC-ND license*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0168365911008856
dc.identifier.doi10.1016/j.jconrel.2011.09.079
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2011 Elsevier under CC BY-NC-ND license
Except where otherwise noted, this item's license is described as © 2011 Elsevier under CC BY-NC-ND license